Why join the CIDP program?
Reduce the time for chronic inflammatory demyelinating polyradiculoneuropathy drug development
All your medical data in one place
Follow new clinical trials
Make your de-identified health information part of multiple research projects
Our work with CIDP research
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-related neurological condition that causes damage to peripheral nerves. Most patients are diagnosed between the ages of 40 and 60. In CIDP, nerve damage causes progressive leg and arm weakness that makes it difficult to walk, go up stairs, and perform fine motor skills. Current treatments for CIDP do not work for everyone, so new treatments are still needed.
The latest on our research: RDMD is currently recruiting patients for a new phase II clinical trial for CIDP. Patients cleared by RDMD are then more likely to qualify for the trial. This is the first time RDMD has been involved in a phase II trial, and we are learning how we can make this process even simpler and easier for patients in the future.
How it works
1. Sign up
Create your private account and review our research consent (takes about 10 minutes)
2. We get to work
We do all the behind-the-scenes work to retrieve and process your records
3. Empower research
Track your contribution to research projects and, based on your records, find out if you qualify for new clinical trials based on your records
Our values & principles.
We believe that the only way to keep data accessible to the researchers who need it is by enabling patients to own and control their own data. Patients decide for themselves whether they want to privately and securely contribute to research, rather than having the decision made on their behalf.
We aim to make useful data accessible to all researchers who have legitimate research questions or research programs. For academic research, we offer access without charge. We take research ethics seriously, and we have policies in place to ensure that research is conducted with integrity.
We don’t like to take sides—we give all members of the community the option to get involved. Success in rare disease research takes a village and we always welcome additional collaborators who can advance and benefit from the mission.
Our primary mission is to accelerate drug development, so we prioritize generating insights specifically relevant to therapeutic research. We invest deeply in quality, security, and compliance to make this a reality.